ArticleFrontiers in oncology2025
Burden of malignant neoplasm of bone and articular cartilage from 1990 to 2021 and its predictions to 2030 in China compared with world.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- What are the predominant factors predicting trend of post-traumatic growth for patients after bone tumour surgery? A longitudinal observational study.BMC psychology · 2026Observational
- Global burden and forecast of malignant neoplasms of bone and articular cartilage from 1990 to 2030.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To comprehensively examine the incidence and mortality of malignant neoplasms of bone and articular cartilage (MNBAC) in China compared with the world, as well as its age-specific patterns and sex disparities. Methods: The MNBAC burden in China and the world was systematically assessed from 1990 to 2021 based on the Global Burden of Disease 2021, including incidence and mortality data. The estimated annual percentage change was calculated. The pattern of age and gender distribution was carried out. The future trends of MNBAC incidence and mortality through 2030 were predicted using the Bayesian age-period-cohort model. Results: From 1990 to 2021, China experienced rising trends in both the incidence and mortality of MNBAC, increasing at a much faster pace than the world. Before 2005, crude incidence and mortality rates in China increased but plateaued thereafter. In contrast, age-standardized rates displayed a decreasing trend from 2005 onward. During this period, the world experienced relatively stable incidence and mortality rates. The incidence and mortality rates of MNBAC increase with age. The MNBAC burden is higher in males. The rise in incidence and mortality rate in China was predominantly in the elderly. The burden prediction for MNBAC to 2030 showed that China would experience a more significant drop in incidence and mortality rates for MNBAC, along with a decrease in the incidence and mortality cases. Conclusions: From 1990 to 2021, the MNBAC burden in China remains heavy, with incidence and mortality increasing much faster than in the world. The projection results indicate a promising outlook for the future, which is encouraging news. Men and the elderly should be the key target for the public health policies of MNBAC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.